the identification of influenza A virus and influenza B virus from a patient's specimen in under 30 minutes. It also develops and commercializes genetically engineered cell-based detection products for the pharmaceutical and biotechnology industry with a focus on pharmacology assays and products that measure drug clearance and anti-viral interventions with drugs and vaccines. In addition, the company provides an assortment of products for specimen collection, specimen transport, multi-virus cell culture amplification, and sensitive and specific virus detection using monoclonal antibody kits and reagents. Further, it offers respiratory, herpes family, chlamydia, and enterovirus testing solutions; monolayer cell line products for use in diagnosing and detecting viruses that cause human illness; C. difficile toxin; flocked swabs and UTM; and media and supplements, including prepared media, salt solutions, antibiotic solutions, and trypsin solutions. Furthermore, the company provides products and services for non-diagnostic applications, including in vitro toxicology and metabolism products and services, such as primary hepatocytes and hepatocyte-based assays. It also supports educational programs for influenza A, influenza B, RSV, MPV, Adenovirus, and Parainfluenza 1, 2, and 3 through direct speaker programs and educational grants, as well as Internet-based education programs. The company was formerly known as Molecular Diagnostics, Inc. Diagnostic HYBRIDS, Inc. was founded in 1983 and is based in Athens, Ohio.